EE03746B1 - Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm - Google Patents

Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm

Info

Publication number
EE03746B1
EE03746B1 EE9800393A EE9800393A EE03746B1 EE 03746 B1 EE03746 B1 EE 03746B1 EE 9800393 A EE9800393 A EE 9800393A EE 9800393 A EE9800393 A EE 9800393A EE 03746 B1 EE03746 B1 EE 03746B1
Authority
EE
Estonia
Prior art keywords
phenyl
furanone
cyclooxygenase
methylsulfonyl
treatment
Prior art date
Application number
EE9800393A
Other languages
English (en)
Estonian (et)
Other versions
EE9800393A (et
Inventor
Hancock Bruno
Winters Conrad
Gertz Barry
Ehrich Elliot
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada & Co. / Merck Frosst Canada &Cie.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03746(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co., Inc., Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. filed Critical Merck & Co., Inc.
Publication of EE9800393A publication Critical patent/EE9800393A/xx
Publication of EE03746B1 publication Critical patent/EE03746B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
EE9800393A 1996-05-17 1997-05-13 Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm EE03746B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (2)

Publication Number Publication Date
EE9800393A EE9800393A (et) 1999-06-15
EE03746B1 true EE03746B1 (et) 2002-06-17

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800393A EE03746B1 (et) 1996-05-17 1997-05-13 Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm

Country Status (28)

Country Link
US (1) US6063811A (is)
EP (1) EP0910368A1 (is)
JP (1) JPH11512754A (is)
KR (1) KR100373622B1 (is)
CN (1) CN1140267C (is)
AR (1) AR012014A1 (is)
AU (1) AU3004997A (is)
BG (1) BG103000A (is)
BR (1) BR9709097A (is)
CA (1) CA2254061C (is)
CO (1) CO5050370A1 (is)
CZ (1) CZ291463B6 (is)
DZ (1) DZ2200A1 (is)
EA (1) EA001596B1 (is)
EE (1) EE03746B1 (is)
HR (1) HRP970262A2 (is)
HU (1) HUP9902889A3 (is)
ID (1) ID16921A (is)
IL (1) IL126899A (is)
IS (1) IS4891A (is)
MY (1) MY116201A (is)
NO (1) NO985342D0 (is)
NZ (1) NZ332670A (is)
PE (1) PE66998A1 (is)
PL (1) PL188649B1 (is)
SK (1) SK284330B6 (is)
TR (1) TR199802345T2 (is)
WO (1) WO1997044028A1 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
IL153303A0 (en) 2000-06-13 2003-07-06 Wyeth Corp Analgesic and anti-inflammatory compositions conaining cox-2 inhibitors
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP2004506680A (ja) * 2000-08-18 2004-03-04 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2002303577B2 (en) * 2001-05-04 2006-06-08 Merck & Co., Inc. Method and compositions for treating migraines
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
MXPA04002798A (es) * 2001-09-26 2004-07-05 Pharmacia Corp Composiciones de valdecoxib de disgregacion intraoral.
BR0213152A (pt) * 2001-10-10 2004-10-19 Pharmacia Corp Composições de valdecoxib de desintegração intraoral preparadas por processo de secagem por pulverização
AR038747A1 (es) * 2002-03-07 2005-01-26 Novartis Ag Una composicion farmaceutica solida para tratar un desorden o condicion dependiente de la ciclooxigenasa-2
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
HUT74986A (en) * 1994-01-10 1997-03-28 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them

Also Published As

Publication number Publication date
EP0910368A1 (en) 1999-04-28
ID16921A (id) 1997-11-20
EA001596B1 (ru) 2001-06-25
CN1140267C (zh) 2004-03-03
IS4891A (is) 1998-11-10
IL126899A0 (en) 1999-09-22
HK1021623A1 (en) 2000-06-23
CZ291463B6 (cs) 2003-03-12
BR9709097A (pt) 1999-08-03
AR012014A1 (es) 2000-09-27
HUP9902889A2 (hu) 2002-01-28
US6063811A (en) 2000-05-16
NO985342L (no) 1998-11-16
CN1225010A (zh) 1999-08-04
PE66998A1 (es) 1998-10-24
NZ332670A (en) 2000-07-28
PL329940A1 (en) 1999-04-26
JPH11512754A (ja) 1999-11-02
PL188649B1 (pl) 2005-03-31
CA2254061A1 (en) 1997-11-27
EA199801017A1 (ru) 1999-04-29
CZ373898A3 (cs) 1999-06-16
WO1997044028A1 (en) 1997-11-27
MY116201A (en) 2003-11-28
KR20000011082A (ko) 2000-02-25
TR199802345T2 (xx) 1999-03-22
DZ2200A1 (fr) 2004-06-20
CA2254061C (en) 2003-12-02
EE9800393A (et) 1999-06-15
SK284330B6 (sk) 2005-01-03
HRP970262A2 (en) 1998-06-30
KR100373622B1 (ko) 2003-07-12
HUP9902889A3 (en) 2002-04-29
NO985342D0 (no) 1998-11-16
SK156798A3 (en) 2000-01-18
IL126899A (en) 2004-03-28
BG103000A (en) 1999-09-30
AU3004997A (en) 1997-12-09
CO5050370A1 (es) 2001-06-27

Similar Documents

Publication Publication Date Title
EE03746B1 (et) Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
ATE165973T1 (de) Sumatriptan enthaltende arzneimittel
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
IL178072A (en) Use of monoesters of probucol or a pharmaceutically acceptable salt thereof for preparing medicaments for the treatment of cardiovascular and inflammatory disease
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
FI971188L (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
SE9700885D0 (sv) New pharmaceutical formulation
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
MX9708803A (es) Compuestos biaromaticos de propinilo o dienilo.
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
HUP9902135A2 (hu) (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására
PT1150681E (pt) Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
AU8015398A (en) Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity
HUP0402092A3 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
MA26650A1 (fr) Oxo-thia -azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses.
SE9902937D0 (sv) Pharmaceutical compositions
MA26670A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de nos, leur preparation et leur utilisation

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120513